Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Tax Provisions (2021 - 2025)

Kiniksa Pharmaceuticals International's Tax Provisions history spans 5 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 155.91% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $29.9 million, up 2837.21%, while the annual FY2025 figure was $29.9 million, 2837.21% up from the prior year.
  • Tax Provisions reached $9.1 million in Q4 2025 per KNSA's latest filing, up from $8.7 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $187.9 million in Q4 2022 to a low of -$177.4 million in Q3 2022.
  • Average Tax Provisions over 5 years is $628950.0, with a median of $2.4 million recorded in 2022.
  • The largest YoY upside for Tax Provisions was 67238.71% in 2022 against a maximum downside of 150203.39% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $279000.0 in 2021, then soared by 67238.71% to $187.9 million in 2022, then crashed by 112.13% to -$22.8 million in 2023, then grew by 28.81% to -$16.2 million in 2024, then soared by 155.91% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Tax Provisions are $9.1 million (Q4 2025), $8.7 million (Q3 2025), and $5.0 million (Q2 2025).